{"id":926711,"date":"2026-01-13T08:44:37","date_gmt":"2026-01-13T13:44:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\/"},"modified":"2026-01-13T08:44:37","modified_gmt":"2026-01-13T13:44:37","slug":"briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\/","title":{"rendered":"BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS\u2122 Patient"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>[IMAGES BELOW] 11-month sustained complete resolution of lung metastasis observed in Bria-OTS Phase 1\/2a metastatic breast cancer study.<br \/><\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>No treatment limiting toxicities reported.<br \/><\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Patient maintained stable disease at all other evaluable sites.<br \/><\/em><br \/>\n          <\/strong>\n        <\/li>\n<\/ul>\n<p align=\"justify\">PHILADELPHIA and VANCOUVER, British Columbia, Jan.  13, 2026  (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announces the durable and sustained complete resolution of a lung metastasis in a patient with metastatic breast cancer (MBC) treated with Bria-OTS, BriaCell\u2019s personalized off the shelf immunotherapy. The patient is hormone receptor-positive (HR+), HER2-negative.<\/p>\n<p align=\"justify\">The first patient enrolled in the Bria-OTS study, a 78-year-old woman with advanced metastatic breast cancer and multiple prior treatment failures, achieved complete (100%) resolution of a lung metastasis following four doses of Bria-OTS single agent therapy. The complete response, initially observed at 2 months (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OkQ6uqy52LQpHAFj3J4nnwDAjvf2EDOxXKw1HVrUSanbGPdg6AMLLG1OXuIxglTkeVeTciRzXzkkFdBOndXtHqODQRobuPEtTDKOX0x5UnabMltQtT0Ja7m-zQ6xgLBrtm6xWjd1ErcmjykcbesNIzTUDzdrpu6AGxkU6sF7Cg06S1JhsttTQiDYDVwfo0ei\" rel=\"nofollow\" target=\"_blank\">previously reported<\/a>), was subsequently confirmed at 4 months (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OkQ6uqy52LQpHAFj3J4nn2yF_FDipcT0Mb6pPec68RNoPyeRNKGMhF_ovf_A5uoPiTwpUMVVYuARhM_LLgWqSbBC2NEmIiAE12swoRvsnIg6PZGdGUPuogtAla7eszvLziGwLZYXS3v1N5tqLW-oz57jD_JfUaJMgCCMbv7mTSFU0jjlxMURMpGVi3edsbaT\" rel=\"nofollow\" target=\"_blank\">previously reported<\/a>), 6 months (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OkQ6uqy52LQpHAFj3J4nn5sa1F95DC6JzIqRdRIHW05cAPOIRhIaB3hDEJPX2i4RQGrJACEV6CM4_5OPLvNsVm0t3cb79YeYxsNs5NG87lmyitlb5BBAuoUrOljLTUXsQPOUDXO6f9VxbRmwbH-eJ4RDKDn0rI83sTN2Fhl9f6o3Pbmh9rRgAkCZO4dSrh_v\" rel=\"nofollow\" target=\"_blank\">previously reported<\/a>), and now at 11 months. The patient received 17 cycles of Bria-OTS, completed 12 months of the study, and remains in survival follow-up.\u00a0<\/p>\n<p align=\"left\">\n        <strong>Figure 1: Treatment with Bria-OTS monotherapy resulted in 100% resolution of tumor in the right lung of the metastatic breast cancer (MBC) patient following 2 months of therapy and confirmed at 4, 6, and 11 months of therapy<\/strong><br \/>\n        <sup><br \/>\n          <strong>1<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> (axial and coronal views)<\/strong>\n      <\/p>\n<p align=\"center\">\n        \n      <\/p>\n<p align=\"justify\">The Phase 1 dose escalation portion of the study is complete and the Phase 2a portion, evaluating combination of Bria-OTS with an immune checkpoint inhibitor, is now underway.<\/p>\n<p align=\"justify\">\u201cThe sustained clinical response observed in this late-stage MBC patient, who had previously progressed through multiple prior treatments is remarkable,\u201d stated Neal S. Chawla MD, Director at the Sarcoma Oncology Center, Santa Monica, CA, and Principal Investigator for the Bria-OTS study. \u201cWe are excited to further evaluate Bria-OTS in combination with an immune checkpoint inhibitor in metastatic breast cancer.\u201d<\/p>\n<p align=\"justify\">\u201cThese clinical findings reinforce our confidence in the therapeutic potential and safety of the Bria-OTS platform,\u201d added Dr. William V. Williams, BriaCell\u2019s President and CEO. \u201cOur team remains committed to advancing our novel therapeutic approach with the goal of making a meaningful difference for patients with metastatic breast cancer, particularly those with limited treatment options.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About Bria-OTS<\/strong>\n      <\/p>\n<p align=\"justify\">Bria-OTS is a next generation, off-the-shelf personalized immunotherapy based on BriaCell\u2019s lead candidate Bria-IMT currently being evaluated in a Phase 1\/2a study (ClinicalTrials.gov identifier: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=op4phKn0VGRNqTKWXdrq3jKH1oPEcK9izEyhJreFR0-3cEWwxbk97pUwiS4Y38sfriSUCtkrDMcFq_aFeYtxr0AfkA7HU0QTARwMwzrf2GNGxneq5eS5xIczQGm6RJGcqV-YyddClqYxr1XO-dQ-mg==\" rel=\"nofollow\" target=\"_blank\">NCT06471673<\/a>) in patients with metastatic recurrent breast cancer. The trial includes both monotherapy dose escalation and checkpoint inhibitor combination dose expansion cohorts. The Company has recently entered the dose expansion phase.<\/p>\n<p align=\"justify\">\n        <strong>About BriaCell Therapeutics Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qcG6-ys8cE0mmjMCEcgm72NOjGudbtEKus1hjRQarmdEqt09gBqp2FEbkzOzxy4QPjBFxi_22iqYApAKE3_uMYDEtJZ_DRwehqh2AvlEajo=\" rel=\"nofollow\" target=\"_blank\">https:\/\/briacell.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release include statements regarding: BriaCell continuing the Phase 1\/2a Bria-OTS study and reproducing similar results in patients with MBC and other cancers; the use of the Bria-OTS platform as monotherapy; and Bria-OTS\u2019s validation as a personalized immunotherapy approach. Forward-looking statements may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading \u201cRisks and Uncertainties\u201d in the Company\u2019s most recent Management\u2019s Discussion and Analysis, under the heading \u201cRisk Factors\u201d in the Company\u2019s most recent Annual Information Form, and under \u201cRisks and Uncertainties\u201d in the Company\u2019s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company\u2019s profiles on SEDAR+ at\u00a0<strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OEOLD5_lz4LZ9KuYVXc1lGYDseiTxcP3InfCOL_bwWL4CLT-v2x838D9JTAgkwzqNeqQJNcWxI2uJJ3OQ5tYNlQQ3BmxAxzJBw1DESbc_H8=\" rel=\"nofollow\" target=\"_blank\">www.sedarplus.ca<\/a><\/strong>\u00a0and on EDGAR at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OEOLD5_lz4LZ9KuYVXc1lGpT9ZWc-nEpty73-LL7SbvBOK4_HHHXkEpnW-GBYa5E_y_uuf1xuzhLLSdYkQrUmw==\" rel=\"nofollow\" target=\"_blank\"><strong>www.sec.gov<\/strong><\/a>. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.<\/p>\n<p align=\"justify\">Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/p>\n<p align=\"left\">\n        <strong>Contact Information<\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>William V. Williams, MD<br \/>President &amp; CEO<br \/>1-888-485-6340<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9dejQa2xc1XGnOWiwb4W9EKeeDa1o8EHuWVN_PBZXe5ahVv3wedry9xlwHShOJI_6ZD2gb8uG2EgcLR9sU_7qCNLELuxnCgWaLFhYFUaHsU=\" rel=\"nofollow\" target=\"_blank\">info@briacell.com<\/a>\u00a0<\/p>\n<p align=\"left\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aEm5Kqa9fqZZ_xH4Klt-TtOJEAD4UZpn2HTpfBL_OxpsdRrRUwwTwQ-UqFgmPJS8sSzLJTOSjrYHRVoqfQNBtbrp9IFU2Uu_el7-gS23Vuo=\" rel=\"nofollow\" target=\"_blank\">investors@briacell.com<\/a>\n      <\/p>\n<p align=\"justify\">\n        <sup>1<\/sup> Note that the other white dots in the lungs are blood vessels.<\/p>\n<p>A photo accompanying this announcement is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qcG6-ys8cE0mmjMCEcgm7yCpMLRqSbH3h0iWc4WlarGlaDczwp18rEev0ytfcLE6PejBu47mfNiEc7mYz_DOYtuBtp0lOAVRUf7-HbGTesHWjlt0-Za8kdryACh4Bxi69RCBkPofpoRAQaxsCB1uJAk1Bv6HfYb4tFKZMy_ev9Xacimaow6hY-t5LBnQWpv-yYZLCuV_oFNGaZW4KPWsTImWq0JyjIIHvVla8JIGXcTA_MVttqpRAPuUR4ohWOlYaQVe9jsqN8gpDKAkxmt_yA==\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/be299ddd-4e02-4bf0-8b5a-f704f172076e<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNDUyMCM3MzU3MDc2IzIwOTA2NTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YzQxYzE0ZDQtZWQwMS00MTU3LTkyZjMtMDU1YTNkNjNkNjVmLTExMDIyMjktMjAyNi0wMS0xMy1lbg==\/tiny\/BriaCell-Therapeutics-Corp-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>[IMAGES BELOW] 11-month sustained complete resolution of lung metastasis observed in Bria-OTS Phase 1\/2a metastatic breast cancer study. No treatment limiting toxicities reported. Patient maintained stable disease at all other evaluable sites. PHILADELPHIA and VANCOUVER, British Columbia, Jan. 13, 2026 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announces the durable and sustained complete resolution of a lung metastasis in a patient with metastatic breast cancer (MBC) treated with Bria-OTS, BriaCell\u2019s personalized off the shelf immunotherapy. The patient is hormone receptor-positive (HR+), HER2-negative. The first patient enrolled in the Bria-OTS study, a 78-year-old woman with advanced metastatic breast cancer and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS\u2122 Patient&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-926711","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS\u2122 Patient - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS\u2122 Patient - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"[IMAGES BELOW] 11-month sustained complete resolution of lung metastasis observed in Bria-OTS Phase 1\/2a metastatic breast cancer study. No treatment limiting toxicities reported. Patient maintained stable disease at all other evaluable sites. PHILADELPHIA and VANCOUVER, British Columbia, Jan. 13, 2026 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announces the durable and sustained complete resolution of a lung metastasis in a patient with metastatic breast cancer (MBC) treated with Bria-OTS, BriaCell\u2019s personalized off the shelf immunotherapy. The patient is hormone receptor-positive (HR+), HER2-negative. The first patient enrolled in the Bria-OTS study, a 78-year-old woman with advanced metastatic breast cancer and &hellip; Continue reading &quot;BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS\u2122 Patient&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-13T13:44:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNDUyMCM3MzU3MDc2IzIwOTA2NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS\u2122 Patient\",\"datePublished\":\"2026-01-13T13:44:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\\\/\"},\"wordCount\":806,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNDUyMCM3MzU3MDc2IzIwOTA2NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\\\/\",\"name\":\"BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS\u2122 Patient - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNDUyMCM3MzU3MDc2IzIwOTA2NTg=\",\"datePublished\":\"2026-01-13T13:44:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNDUyMCM3MzU3MDc2IzIwOTA2NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNDUyMCM3MzU3MDc2IzIwOTA2NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS\u2122 Patient\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS\u2122 Patient - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\/","og_locale":"en_US","og_type":"article","og_title":"BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS\u2122 Patient - Market Newsdesk","og_description":"[IMAGES BELOW] 11-month sustained complete resolution of lung metastasis observed in Bria-OTS Phase 1\/2a metastatic breast cancer study. No treatment limiting toxicities reported. Patient maintained stable disease at all other evaluable sites. PHILADELPHIA and VANCOUVER, British Columbia, Jan. 13, 2026 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announces the durable and sustained complete resolution of a lung metastasis in a patient with metastatic breast cancer (MBC) treated with Bria-OTS, BriaCell\u2019s personalized off the shelf immunotherapy. The patient is hormone receptor-positive (HR+), HER2-negative. The first patient enrolled in the Bria-OTS study, a 78-year-old woman with advanced metastatic breast cancer and &hellip; Continue reading \"BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS\u2122 Patient\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-13T13:44:37+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNDUyMCM3MzU3MDc2IzIwOTA2NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS\u2122 Patient","datePublished":"2026-01-13T13:44:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\/"},"wordCount":806,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNDUyMCM3MzU3MDc2IzIwOTA2NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\/","name":"BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS\u2122 Patient - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNDUyMCM3MzU3MDc2IzIwOTA2NTg=","datePublished":"2026-01-13T13:44:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNDUyMCM3MzU3MDc2IzIwOTA2NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNDUyMCM3MzU3MDc2IzIwOTA2NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-patient\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS\u2122 Patient"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/926711","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=926711"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/926711\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=926711"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=926711"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=926711"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}